Drug class:Insulin Medically reviewed byMelisa Puckey, BPharm. Last updated on Dec 6, 2023. What is insulin glargine? Insulin glargine is a long-acting insulin used to treat type 1 andtype 2 diabetesin certain patients to improve and maintain blood glucose levels. Insulin glargine is a man-...
Insulin Glargine Glargine insulin of hexameric form progressively disengages from the bound state, in which it is supposed to be initially residing, with a rate proportional to cB and with a proportionality factor κ (mL/IU/min). From: Personalized Predictive Modeling in Type 1 Diabetes, 2018 ...
Insulin Glargine Plus Lixisenatide In subject area: Medicine and Dentistry iGlarLixi is a titratable fixed-ratio combination of insulin glargine (iGlar) and lixisenatide (Lixi) that is administered once daily. From: Diabetes Research and Clinical Practice, 2020...
Objective: Present Phase IV Trial is aimed at evaluating the immunogenicity, safety, and efficacy of Wockhardt's insulin glargine, Glaritus(R) in compariso... SK Sharma,AK Ajmani,P Khosla,... - 内分泌与新陈代谢疾病期刊(英文) 被引量: 0发表: 2018年 GLP-1 PROMOTER MEDIATED INSULIN EXPRESSIO...
Patients currently on basal insulin 30-60 units/day with or without a GLP-1 agonist: insulin Glargine 30 units/lixisenatide 10 mcg subcutaneous once a day Dosage Considerations – Should be Given as Follows: See “Dosages” What Other Drugs Interact with Insulin Glargine-Lixisenatide?
These guidelines are not intended to interfere with clinical judgment. Rather, they are intended to assist practitioners in providing consistent, high quality cost effective care.Deborah KhachikianPharm.D
Medically reviewed by Philip Thornton, DipPharm. Last updated on Feb 16, 2024.Other side effects Serious side effects Professional info FAQ Applies to insulin glargine / lixisenatide: subcutaneous solution.Other side effectsSome side effects of insulin glargine / lixisenatide may occur that usually do...
14 We used the IQVIA Formulary Impact Analyzer (FIA)15 to derive the number and source (manufacturer, PBM, or state/federal) of insulin glargine pharmacy transactions with co-payment offsets from Basaglar market entry to December 31, 2018. A transaction is counted as a co-payment offset if...
What is described is a pharmaceutical formulation for intranasal delivery of insulin to a patient, comprising an aqueous mixture of human insulin, a solubilizing agent, a surface ac
Recently, patent U.S. Pat. No. 5,656,722 describes a novel protein structure similar to insulin called GLARGINE® contained in a formulation. A completely different route for obtaining a form for prolonged release of protein is disclosed in patent U.S. Pat. No. 5,904,936 (EP-B-0 734...